Management of advanced gastric cancer

Expert Review of Gastroenterology and Hepatology

Volumn 6, Issue 2, 2012, Pages 199-209

  Price, Timothy J ^a   Shapiro, Jeremy D ^b   Segelov, Eva ^c   Karapetis, Christos S ^d   Pavlakis, Nick ^e   Van Cutsem, Eric ^f   Shah, Manish A ^g   Kang, Yoon Koo ^h   Tebbutt, Niall C ⁱ  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h University of Ulsan College of Medicine   (South Korea)

ⁱ AUSTIN HEALTH   (Australia)

Author keywords

chemotherapy; EGFR; gastric cancer; HER2; review; VEGF

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LAPATINIB; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TRASTUZUMAB;

ADVANCED CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FEBRILE NEUTROPENIA; GEOGRAPHIC DISTRIBUTION; HUMAN; LOWER ESOPHAGUS SPHINCTER; LUNG NON SMALL CELL CANCER; NAUSEA; PALLIATIVE THERAPY; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; STOMACH CANCER;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; MOLECULAR TARGETED THERAPY; PRACTICE GUIDELINES AS TOPIC; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84858013655     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.11.103     Document Type: Review

References (76)

1. Garcia M, Jemal A, Ward EM et al. Global Cancer Facts and Figures 2007. American Cancer Society. Atlanta, GA, USA (2007).
2. The Australian Institute of Health and Welfare (AIHW)/Australasian Association of Cancer Registries (AACR).Cancer in Australia: An Overview. AIHW, Canberra, Australia (2008).
3. Cunningham D, Allum WH, Stenning SP et al. MAGIC trial participants. Perioperative chemotherapy versus surgery alone for resectablegastroesophageal cancer. N. Engl. J. Med. 355(1), 11-20 (2006).
4. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345(10), 725-730 (2001).
5. Sakuramoto S, Sasako M, Yamaguchi T. et al. ACTS-GC group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 357(18), 1810-1820 (2007).
6. Wagner AD, Unverzagt S, Grothe W. et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 3, CD004064 (2010).
7. Power DG, Kelsen DP, Shah MA. Advanced gastric cancer - slow but steady progress. Cancer Treat. Rev. 36(5), 384-392 (2010).
8. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J. Gastroenterol. 12(3), 354-362 (2006).
9. Kang YK, Kang WK, Shin D.B. et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: A randomised Phase 3 noninferiority trial. Ann. Oncol. 20(4), 666-673 (2009).
10. Koizumi W, Narahara H, Hara T. et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A Phase 3 trial. Lancet Oncol. 9(3), 215-221 (2008).
11. Cunningham D, Starling N, Rao S. et al. Upper gastrointestinal clinical studies group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358(1), 36-46 (2008).
12. Ross P, Nicolson M, Cunningham D. et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J. Clin. Oncol. 20, 1996-2004 (2002).
13. Webb A, Cunningham D, Scarffe J.H. et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. 15, 261-267 (1997).
14. Yun J, Lee J, Park S.H. et al. A randomised Phase 2 study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. Eur. J. Cancer 46(5), 885-891 (2010).
15. Kim T, hoi SJ, Ahn J.H. et al. A prospective randomised Phase 3 trial of 5-fluorouracil and cisplatin versus epirubicin, cisplatin and 5FU in the treatment of patients with previously untreated advanced gastric cancer. Eur. J Cancer 37(Suppl.
16. Bleiberg H Sargent DJ. GASTRIC meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer. J. Clin. Oncol. 29 2011 (Abstract 4109).
17. Pozzo C, Ohashi Y. GASTRIC project. Meta-analysis of randomized trials assessing the influence of chemotherapy and prognostic factor in advanced/recurrent gastric cancer. J. Clin. Oncol. 27(15) (2009) (Abstract 4550).
18. Van Cutem E, Moiseyenko VM, Tjulandin S. et al. V325 study group. Phase 3 study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the
19. Shah M.A, Stoller R, Shibata S.et al. Random assignment multicenter Phase 2 study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE).Presented at: Gastrointestinal Cancers Symposium 170a. Orlando, FL, USA, 22-24 January 2010.
20. Tebbutt C, Cummins MM, Sourjina T. et al. Randomised, non-comparative Phase 2 study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: The AGITG ATTAX trial. Br. J. Cancer
21. Okies AF, Norman AR, McCloud P. et al. Meta-analysis of the REAL-2 and ML17032 trials: Evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced
22. Haller DG, Cassidy J, Clarke S.J. et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J. Clin. Oncol. 26(13), 2118-2123 (2008).
23. Ma BB, Hui EP, Mok TS. Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol. 11(1), 75-84 (2010).
24. De Vita F, Orditura M, Matano E. et al. A Phase 2 study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br. J. Cancer 992(9), 1644-1649 (2005).
25. Lee HH, Hur H, Kim S.H. et al. Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis. Cancer Res. Treat. 42(1), 18-23 (2010).
26. Guimbaud R, Louvet C, Bonnetain F. et al. Final results of the intergroup FFCD-GERCORFNCLCC 03-07 Phase 3 study comparing two sequences of chemotherapy in advanced gastric cancers. Ann. Oncol. 21(SUPPL8), (Abstract 8010)
27. Price T, Hill M, Norman A. et al. The royal marsden experience of carbolplatin in oesophageal carcinoma. GI Cancer 4(1), 23-26 (2002).
28. Tebutt NC, Norman A, Cunningham D. et al. A multicentre, randomised Phase 3 trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann.
29. Cullnan SA, Moertel CG, Wieand H.S. et al. Controlled evaluation of three drug combinationregimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J. Clin. Oncol. 12(2), 412-416
30. Lee J, Kang W, Lim D.et al. Phase 3 trial of adjuvant capecitabine/cisplatin compared with capecitabine/cisplatin/RT in resected gastric cancer with D2 nodal dissection ARTIST trial: Safety analysis. Gastrointestinal Cancers Symposium 5a.
31. Kochi M, Fujii M, Kanamori N. et al. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients. Cancer Chemother. Pharmacol. 60(5), 693-701 (2007).
32. Tey J, Back MF, Shakespeare T.P. et al. The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. Int. J. Radiat. Oncol. Biol. Phys. 67, 385-388 (2007).
33. Hashimoto K, Mayahara H, Takashima A. et al. Palliative radiation therapy for hemorrhage of unresectable gastric cancer: A single institute experience. J. Cancer Res. Clin. Oncol. 135, 1117-1123 (2009).
34. Kim MM,Rana V, Janjan N.A. et al. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol. 47, 421-427
35. Asakura , Hashimoto T, Harada H. et al. Palliative radiotherapy for bleeding from advanced gastric cancer: Is a schedule of 30 Gy in 10 fractions adequate? J. Cancer Res. Clin. Oncol. 137(1),
36. Sun J, Su YH, Zeng Z.C. et al. Consideration of the role of radiotherapy for abdominal lymph node metastases in patients with recurrent gastric cancer. Int. J. Radiat. Oncol. Biol. Phys. 77(2),
37. Bang Y, Chung H, Xu J. et al. Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J. Clin. Oncol. 27(15s)
38. Gravalos C. Jimeno A. HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann. Oncol. 19(9). 1523-1529 (2008).
39. rabsch H, Sivakumar S, Gray S. et al. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol. 32(1-2), 57-65 (2010).
40. ang J, Van Cutsem E, Feyereislova A. et al. ToGA trial investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal
41. Albarello L.Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv. Anat. Pathol. 18(1), 53-59 (2011).
42. ilous M, Osamura RY, Rüschoff J. et al. Comment: HER-2 amplification is highly homogenous in gastric cancer. Hum. Pathol. 41(2), 304-305 (2010).
43. opp R, Ruge M, Rothbauer E. et al. Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res. 22, 1161-1167 (2002).
44. into C, Di Fabio F, Siena S. et al. Phase 2 study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).Ann. Oncol. 18, 510-517
45. into C, Di Fabio F, Barone C. et al. Phase 2 study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).Br. J.
46. Han S, Park SR, Lee K. et al. Phase 2 study and biomarker analysis of cetuximab in combination with oxaliplatin, 5-FU, leucovorin as first-line treatment in patients with recurrent or metastatic gastric cancer. J. Clin. Oncol. 26, 225s (2008).
47. Lordick F.Lorenzen S.Hegewisch-Becker S.et al. Cetuximab plus weekly oxaliplatin/5-FU/FA in first line metastatic gastric cancer. Final results from a multicenter Phase 2 study of the AIO Upper GI Study Group. J. Clin. Oncol. 25(18s) (2007) (Abstract 4526).
48. Liu Z. Liu L.;Li M.et al. Epidermal growth factor receptor mutation in gastric cancer Pathology 43 3 234-238 2011
49. Ferry DR, Anderson M, Beddard K. et al. A Phase 2 study of gefitinib monotherapy in advanced esophageal adenocarcinoma: Evidence of gene expression, cellular, and clinical response. Clin. Cancer Res. 13, 5869-5875 (2007).
50. Janmaat ML, Gallegos-Ruiz MI, Rodriguez J.A. et al. Predictive factors for outcome in a Phase 2 study of gefitinib in second-line treatment of advanced esophageal cancer patients. J. Clin. Oncol. 24, 1612-1619 (2006).
51. Dragovich T, McCoy S, Fenoglio-Preiser CM.et al. Phase 2 trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J. Clin. Oncol. 24, 4922-4927 (2006)
52. Fondevila C, Metges JP, Fuster J. et al. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br. J. Cancer 90, 206-215 (2004).
53. Yao JC, Wang L, Wei D.et al Association between expression of transcription factor S p1 and atients with resected gastric cancer. Clin. Cancer Res. 10 4109-4117 2004.
54. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter Phase 2 study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J. Clin. Oncol. 24, 5201-5206 (2006).
55. nzinger PC, Fidias P, Meyerhardt J.et al Phase 2 study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. Presented at: Gastrointestinal Cancers Symposium. San Francisco CA, USA,
56. an Y, Ohtsu A, Van Cutsem E. et al. AVAGAST: A randomized, double-blind, placebo-controlled, Phase 3 study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC).J. Clin.
57. ang Y, Kang Y, Kang. et al. Sunitinib as second-line treatment for advanced gastric cancer: Preliminary results from a Phase 2 study. J. Clin. Oncol. 25, 223s
58. Sun W, Powell M, O'Dwyer P.J. et al. Phase 2 study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J. Clin. Oncol. 28, 2947-2951 (2010).
59. Wesolowski R Lee C, Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol. 10 9 903-912
60. Assersohn L, Brown G, Cunningham D, et al. Phase 2 study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann. Oncol. 15(1 64-69 2004
61. hun JH, Kim HK, Lee J.S. et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn. J. Clin. Oncol. 34(1 8-13 2004
62. Hironaka S, Zenda S, Boku N. et al. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 9(1 14-18 2006
63. ee JL Ryu MH, Chang H.M. et al. A Phase 2 study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother. Pharmacol. 61(4 631-637 2008
64. ym S, Chang HM, Kang H.J. et al. A Phase 2 study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer Chemother. Pharmacol. 63 1, 1 1-8 2008
65. oi T, Muro K, Boku N. et al. Multicenter Phase 2 study of everolimus in patients with previously treated metastatic gastric cancer. J. Clin. Oncol. 28(11), 1904-1910 (2010
66. pratlin J. Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-. Curr. Oncol. Rep. 13(2).97-102
67. oehle M, Mueller A, Hartmann J.T. et al. An open-label, multicentre biomarker-oriented AIO Phase 2 trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur. J. Cancer 47 101511-1520 2011
68. old PJ, Goldman B, Iqbal S. et al. Cetuximab as second-line therapy in patients with metastatic esophageal cancer: A Phase 2 Southwest Oncology Group study (Abstract).J. Clin.
69. echt JR, Urba SG, Koehler M. et al. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: Phase 2 efficacy and biomarker analyses. Presented at: Gastrointestinal Cancers Symposium #43a. Orlando, FL, USA,
70. hau I, Norman AR, Ross PJ.et al. Multivariate prognostic factor analysis and second-line treatment in locally advanced and metastatic oesophago-gastric cancer - pooled analysis of 1080 patients from three multicentre randomised controlled trials using individual patient data. Presented at: Gastrointestinal Cancers Symposium 5a. FL, USA
71. huss-atience P, Kretzschmar A, Bichev D. et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - a randomised Phase III study of the Arbeitsgemeinschaft Internistische
72. ark SH, Lim DH, Park K. et al. A multicenter, randomized Phase 3 trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC).J. Clin. Oncol.
73. ubaski M, Johnsson A, Fernebro E. et al. Randomized Phase 2 study of sequentialdocetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: The GATAC trial. Gastric cancer taxotere vs. Campto trial (GATAC) study group. Gastric Cancer 13(3155-161 2010
74. l-Batan SE, Hartmann JT, Probst S. et al. Phase 3 trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft Internistische Onkologie. J. Clin. Oncol. 26 9 1435-1442 2008
75. atalano V, Graziano F, Santini D. et al. Second-line chemotherapy for patients with advanced gastric cancer: Who may benefit? Br. J. Cancer 99 9 1402-1407 2008
76. Teml JS, Greer JA, Muzikansky A. et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N. Engl. J. Med. 19, 363(8), 733-742 (2010)